

# Tobias B Polak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3698088/publications.pdf>

Version: 2024-02-01

10  
papers

105  
citations

1936888

4  
h-index

1473754

9  
g-index

11  
all docs

11  
docs citations

11  
times ranked

100  
citing authors

#	ARTICLE	IF	CITATIONS
1	Two decades of targeted therapies in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 651-660.	3.3	33
2	Expanded Access as a source of real-world data: An overview of FDA and EMA approvals. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1819-1826.	1.1	27
3	Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals. <i>BMJ Open</i> , 2022, 12, e052186.	0.8	11
4	Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
5	The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2022, 196, 329-335.	1.2	9
6	Response to Open Peer Commentary "Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs". <i>American Journal of Bioethics</i> , 2020, 20, W4-W5.	0.5	4
7	Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020. <i>BMJ Open</i> , 2022, 12, e058279.	0.8	4
8	The DRUG Access Protocol: access inequality and European harmonisation. <i>Lancet Oncology</i> , The, 2022, 23, e202.	5.1	3
9	Financial considerations in expanded access policy for gene therapies: A tough nut to crack?. <i>Molecular Therapy</i> , 2021, 29, 1936.	3.7	1
10	The predictive value of a positive phase II ASH abstract for peer-reviewed publication and progression to phase III. <i>Blood</i> , 2022, , .	0.6	1